The US Food and Drug Administration (FDA) approved bepirovirsen, marketed as Hibsago, in combination with existing antiviral therapy for adults without cirrhosis who have chronic hepatitis B virus (HBV) infection.
The first-in-class drug is intended for patients who have received antiviral therapy for at least 6 months, have suppressed HBV viral DNA levels, and have hepatitis B surface antigen levels of 3000 IU/mL or less. The antisense oligonucleotide works by targeting viral genetic material and interfering with replication.
In 2 clinical trials, 24% of patients who received bepirovirsen met criteria to stop their background antiviral therapy, compared with none in the placebo group. About 6 months after stopping all hepatitis B treatment, nearly 20% of treated patients maintained viral control. Still, the drug carries a boxed warning for serious liver reactions and thrombocytopenia.
no comments (yet)